Virnext and VirPath laboratory are proud to be associated with Axo Science and EPIMOD companies as part of the SurVir public-private consortium, which aims to develop an automated platform for rapid detection of a wide range of respiratory pathogenic viruses. This public-private consortium has validated an initial proof of concept on various influenza A/B viruses and the Omicron variant of the SARS-CoV-2 virus. The second phase of the research programm will now be implemented in our BSL-2 and BSL-3 laboratories within the Innovation Center in Biodistrict Gerland.

This R&D Booster project, accredited by the Lyonbiopôle healthcare competitiveness cluster and supported by the Region Auvergne-Rhône-Alpes Innovation Fund and Bpifrance, illustrates the ability of the academic and industrial players in our regional ecosystem to mobilize and work in synergy to implement innovative projects of strategic interest in the fight against viral infections, thereby strengthening the national and international positioning of our Auvergne-Rhône-Alpes region to meet the major challenges of public health.